EXPECT is the Xolair® Pregnancy Registry: An Observational Study Of The Use and Safety Of Xolair® (Omalizumab) During Pregnancy
EXPECT Xolair Pregnancy Registry is Now Enrolling Patients!
Patient Enrollment Criteria
Pregnant women who have taken Xolair within 8 weeks of conception or during pregnancy are eligible to enroll in EXPECT.
For more information please select one of the following:
| For Patients Click here |
For Healthcare Providers Click here |
Or call 1 (866) 4XOLAIR (496-5247), Option 3
8467900 XOL-9480
